Literature DB >> 17689285

Epidermal growth factor receptor inhibitors enhance susceptibility to Fas-mediated apoptosis in oral squamous cell carcinoma cells.

Masayasu Iwase1, Sayaka Takaoka, Makiko Uchida, Sayaka Yoshiba, Gen Kondo, Hitoshi Watanabe, Masaru Ohashi, Masao Nagumo.   

Abstract

Molecular inhibition of epidermal growth factor receptor (EGFR) signaling is a promising cancer treatment strategy. We examined whether inhibition of EGFR signaling would affect the susceptibility of oral squamous cell carcinoma (OSCC) cells to Fas-mediated apoptosis. Treatment of OSCC cells with an anti-EGFR monoclonal antibody, C225, and an EGFR tyrosine kinase inhibitor, AG1478, which target the extracellular and intracellular domains of the receptor, respectively, inhibited phosphorylation of EGFR and its downstream effector molecule Akt and amplified the induction of Fas-mediated apoptosis. In OSCC cells treated with EGFR inhibitors, Fas-mediated apoptosis was accompanied by caspase-8 activation but not Bid cleavage. Caspase-3 and -8 inhibitors reduced the effect of EGFR inhibitors on Fas-mediated apoptosis in OSCC cells, but a caspase-9 inhibitor did not. These results indicate that the pro-apoptotic activity of EGFR inhibitors in OSCC cells depends on the extrinsic pathway of the caspase cascade. Although EGFR inhibitors did not affect the expression of Fas, the Fas-associated death domain protein, or procaspase-8 in OSCC cells, the inhibition downregulated cellular FLICE-inhibitory protein (c-FLIP). Moreover, knockdown of c-FLIP in HSC-2 cells with a small interfering RNA strongly enhanced Fas-mediated apoptosis. These results suggest that the EGFR signaling pathway may, in part, regulate Fas-mediated apoptosis in OSCC cells through c-FLIP expression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17689285     DOI: 10.1016/j.oraloncology.2007.04.006

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  6 in total

Review 1.  Caspase-8 as a therapeutic target in cancer.

Authors:  Dwayne G Stupack
Journal:  Cancer Lett       Date:  2010-09-03       Impact factor: 8.679

Review 2.  Emerging drugs to treat squamous cell carcinomas of the head and neck.

Authors:  Christopher Fung; Jennifer R Grandis
Journal:  Expert Opin Emerg Drugs       Date:  2010-09       Impact factor: 4.191

3.  Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response.

Authors:  Ramaswamy Bhuvaneswari; Yik Yuen Gan; Khee Chee Soo; Malini Olivo
Journal:  Mol Cancer       Date:  2009-11-02       Impact factor: 27.401

Review 4.  Molecular targeted therapies in head and neck cancer--an update of recent developments-.

Authors:  Martin Goerner; Tanguy Y Seiwert; Holger Sudhoff
Journal:  Head Neck Oncol       Date:  2010-04-14

5.  Luteolin induces apoptosis by activating Fas signaling pathway at the receptor level in laryngeal squamous cell line Hep-2 cells.

Authors:  Hui Zhang; Xiuguo Li; Yuanyuan Zhang; Xinyong Luan
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-01-30       Impact factor: 2.503

6.  Targeting the Anti-Apoptotic Protein c-FLIP for Cancer Therapy.

Authors:  Ahmad R Safa; Karen E Pollok
Journal:  Cancers (Basel)       Date:  2011-06       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.